Target intelligence / Profile preview

Poliovirus type 3 antigen (PV3)

Target
PV3
Molecular classification
Viral antigen, Viral capsid protein, Picornavirus
01

Overview

Poliovirus type 3 (PV3) is one of the three distinct serotypes of Poliovirus, a member of the Enterovirus C species within the Picornaviridae family. The virion is a non-enveloped, icosahedral particle approximately 30 nm in diameter, consisting of a positive-sense single-stranded RNA genome protected by a protein capsid made of 60 protomers, each containing four structural proteins: VP1, VP2, VP3, and VP4. PV3 primarily infects humans through the fecal-oral route, binding to the CD155 receptor on host cells to initiate infection, which can lead to the destruction of motor neurons and subsequent paralytic poliomyelitis. As a therapeutic target, the PV3 virion is the basis for the Salk (inactivated) and Sabin (live-attenuated) vaccines, which are designed to elicit protective mucosal and systemic immunity. Beyond vaccines, the viral capsid is a target for experimental antiviral agents like Pocavir, which aim to block the viral life cycle by preventing the structural transitions required for genome uncoating. Although wild poliovirus type 3 was officially declared eradicated globally in 2019, the antigen remains a critical component of trivalent or bivalent vaccines and a focus of surveillance to manage risks associated with vaccine-derived strains.

Other names
Poliovirus 3PV-3Enterovirus C serotype 3Poliovirus type 3 virion
02

Mechanism of action

Vaccines induce the production of neutralizing antibodies that bind to the viral capsid and prevent attachment to the host receptor CD155. Small molecule capsid inhibitors like Pocavir bind to a hydrophobic pocket within the VP1 protein, stabilizing the capsid to prevent the uncoating and release of viral RNA into the host cell.

03

Biological functions

Viral attachmentViral entryViral uncoatingHost cell receptor bindingRNA genome delivery
04

Disease associations

PoliomyelitisInfectionParalytic polio
05

Safety considerations

Vaccine-associated paralytic poliomyelitis (VAPP) with live-attenuated strainsCirculating vaccine-derived poliovirus (cVDPV) emergenceGenetic reversion to virulenceEnvironmental shedding of vaccine strains
06

Interacting drugs

Inactivated poliovirus vaccine (IPV)

3 more in the full profile.

07

Biomarkers

Serum neutralizing antibody titerViral RNA (RT-PCR)VP1 capsid protein sequenceViral culture

Beyond the preview

Go deeper on Poliovirus type 3 antigen (PV3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poliovirus type 3 antigen (PV3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call